Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5487171 | 0.83 | CYP4F2 (0.50) | CYP4F2CYP4A11FFAR1KDM1AMAOA | |
| SCHEMBL30967881 | 0.81 | FFAR1 (0.51) | CYP4F2CYP4A11FFAR1KDM1AMAOA | |
| SCHEMBL30967880 | 0.81 | FFAR1 (0.51) | CYP4F2CYP4A11FFAR1KDM1AMAOA | |
| SCHEMBL10267695 | 0.80 | FFAR1 (0.55) | FFAR1KDM1AALDH1A1 | |
| SCHEMBL8332767 | 0.79 | MGLL (0.46) | CYP4F2CYP4A11SLC5A1SLC5A2SIGMAR1 | |
| SCHEMBL23116570 | 0.79 | FFAR1 (0.65) | FFAR1ALDH1A1HDAC4 | |
| SCHEMBL21501054 | 0.79 | FFAR1 (0.65) | FFAR1ALDH1A1HDAC4 | |
| SCHEMBL7868650 | 0.79 | FFAR1 (0.65) | FFAR1ALDH1A1HDAC4 | |
| SCHEMBL3042239 | 0.79 | FFAR1 (0.65) | FFAR1ALDH1A1HDAC4 | |
| SCHEMBL10288305 | 0.79 | FFAR1 (0.65) | FFAR1ALDH1A1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714136-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | PEKARI KLAUS | 2009-10-15 | — | — | US | disclosed |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | CYP4F2 1694/4885CYP4A11 1881/4885FFAR1 3294/4885 |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | CYP4F2 1846/4885CYP4A11 2152/4885FFAR1 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.